{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T06:19:43Z","timestamp":1791094783405,"version":"4.1.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":49,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"DOI":"10.1186\/s13063-026-09709-0","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T03:48:45Z","timestamp":1777002525000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Platform for the Evaluation of innovations in Radiation oncology through registry-based conduct of multi-centric pragmatic randomized trials: PERa implementation"],"prefix":"10.1186","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-8393-4073","authenticated-orcid":false,"given":"Philippe","family":"Gigu\u00e8re","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Houda","family":"Bahig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sydney","family":"Westra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Roberge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marc","family":"Bourque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina Laura","family":"Masucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva-Sabrina","family":"Nkurunziza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Freire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Belliveau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny","family":"Duplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Vigneault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pencilla","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"M\u00e9nard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"issue":"3","key":"9709_CR1","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.ijrobp.2015.07.007","volume":"93","author":"IJ Chetty","year":"2015","unstructured":"Chetty IJ, Martel MK, Jaffray DA, et al. Technology for innovation in radiation oncology. Int J Radiat Oncol Biol Phys. 2015;93(3):485\u201392.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"9709_CR2","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1056\/NEJMp1005843","volume":"363","author":"RC Young","year":"2010","unstructured":"Young RC. Cancer clinical trials\u2014a chronic but curable crisis. N Engl J Med. 2010;363(4):306\u20139.","journal-title":"N Engl J Med"},{"issue":"4","key":"9709_CR3","first-page":"471","volume":"84","author":"V Prasad","year":"2011","unstructured":"Prasad V, Cifu A. Medical reversal: why we must raise the bar before adopting new technologies. Yale J Biol Med. 2011;84(4):471\u20138.","journal-title":"Yale J Biol Med"},{"key":"9709_CR4","unstructured":"Publication repository. STAMPEDE. Available from: https:\/\/www.stampedetrial.org\/media-section\/publication-repository\/. Cited 2024 Sep 15."},{"issue":"10","key":"9709_CR5","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1080\/0284186X.2016.1189094","volume":"55","author":"JPM Burbach","year":"2016","unstructured":"Burbach JPM, Kurk SA, Coebergh van den Braak RRJ, et al. Prospective dutch colorectal cancer cohort: an infrastructure for long-term observational, prognostic, predictive and (randomized) intervention research. Acta Oncol. 2016;55(10):1273\u201380.","journal-title":"Acta Oncol"},{"issue":"12","key":"9709_CR6","doi-asserted-by":"publisher","first-page":"e1016","DOI":"10.1200\/JOP.2016.013474","volume":"12","author":"J Hilton","year":"2016","unstructured":"Hilton J, Mazzarello S, Fergusson D, et al. Novel methodology for comparing standard-of-care interventions in patients with cancer. J Oncol Pract. 2016;12(12):e1016\u201324.","journal-title":"J Oncol Pract"},{"key":"9709_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c1066","volume":"340","author":"C Relton","year":"2010","unstructured":"Relton C, Torgerson D, O\u2019Cathain A, et al. Rethinking pragmatic randomised controlled trials: introducing the \u201ccohort multiple randomised controlled trial\u201d design. BMJ. 2010;340:c1066.","journal-title":"BMJ"},{"key":"9709_CR8","unstructured":"TwiCs | Trials within cohorts. twics. Available from: https:\/\/www.twics.global. Cited 2024 Sep 15."},{"issue":"4","key":"9709_CR9","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1177\/1740774520988500","volume":"18","author":"AJ Vickers","year":"2021","unstructured":"Vickers AJ, Vertosick EA, Carlsson SV, et al. Patient accrual and understanding of informed consent in a two-stage consent design. Clin Trials Lond Engl. 2021;18(4):377\u201382.","journal-title":"Clin Trials Lond Engl"},{"issue":"1","key":"9709_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/1740774517746610","volume":"15","author":"AJ Vickers","year":"2018","unstructured":"Vickers AJ, Young-Afat DA, Ehdaie B, et al. Just-in-time consent: the ethical case for an alternative to traditional informed consent in randomized trials comparing an experimental intervention with usual care. Clin Trials Lond Engl. 2018;15(1):3\u20138.","journal-title":"Clin Trials Lond Engl"},{"key":"9709_CR11","unstructured":"R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2024. Available from: https:\/\/www.R-project.org\/."},{"issue":"4","key":"9709_CR12","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.ijrobp.2022.12.055","volume":"116","author":"C Petit","year":"2023","unstructured":"Petit C, Delouya G, Taussky D, et al. PSMA-PET\/CT-guided intensification of radiation therapy for prostate cancer (PSMAgRT): findings of detection rate, effect on cancer management, and early toxicity from a phase 2 randomized controlled trial. Int J Radiat Oncol Biol Phys. 2023;116(4):779\u201387.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"12","key":"9709_CR13","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1001\/jamaoncol.2025.3746","volume":"11","author":"C Belliveau","year":"2025","unstructured":"Belliveau C, Saad F, Duplan D, Petit C, Delouya G, Taussky D, et al. Prostate-specific membrane antigen PET-guided intensification of salvage radiotherapy after radical prostatectomy: a phase 2 randomized clinical trial. JAMA Oncol. 2025;11(12):1431\u20138. https:\/\/doi.org\/10.1001\/jamaoncol.2025.3746.","journal-title":"JAMA Oncol"},{"issue":"1","key":"9709_CR14","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1186\/s12885-022-09283-z","volume":"22","author":"C M\u00e9nard","year":"2022","unstructured":"M\u00e9nard C, Young S, Zukotynski K, et al. PSMA PET\/CT guided intensification of therapy in patients at risk of advanced prostate cancer (PATRON): a pragmatic phase III randomized controlled trial. BMC Cancer. 2022;22(1):251.","journal-title":"BMC Cancer"},{"issue":"5","key":"9709_CR15","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1001\/jamaoncol.2024.0280","volume":"10","author":"NP Verdini","year":"2024","unstructured":"Verdini NP, Bryl KL, Baser RE, et al. Patient-reported outcomes as a recruitment strategy for clinical trial enrollment. JAMA Oncol. 2024;10(5):784\u20138.","journal-title":"JAMA Oncol"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-026-09709-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-026-09709-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-026-09709-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T23:46:45Z","timestamp":1781221605000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13063-026-09709-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9709"],"URL":"https:\/\/doi.org\/10.1186\/s13063-026-09709-0","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]},"assertion":[{"value":"16 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The PERa registry and embedded clinical trials underwent review by institutional Ethics Review Boards. All registry and participants provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Houda Bahig\u2014research grant from Varian Medical Systems and AstraZeneca. Advisory boards and speaker fee from AstraZeneca and EMD Serono. Cynthia Menard\u2014research grants from Varian Medical Systems, Promaxo, Tersera, and Lantheus. All other authors declare no relevant potential competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"437"}}